A Study of Sublingual Immunotherapy in Peanut-allergic Children

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Collaborator: National Center for Complementary and Integrative Health (NCCIH)
• Treatments: Glycerol

Criteria

Inclusion Criteria:

• Peanut IgE > 7kU/L (> 2kU/L for children aged 2 years and under) AND

• History of significant clinical symptoms within 60 minutes after the ingestion of peanuts.

Exclusion Criteria:

• History of severe life-threatening anaphylaxis to peanut, OR

• Medical history that would prevent a DBPCFC to peanut, OR

• Subjects with wheat or oat allergy (which are used in the placebo), OR

• Unable to cooperate with challenge procedures, OR

• Unable to be reached by telephone for follow-up